Pfizer wins bidding war for Metsera with $10B offer

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Metsera has abandoned a deal with Novo Nordisk in favor of a new acquisition offer from Pfizer, ending a high-stakes fight between two large pharmaceutical companies over ownership of a coveted maker of obesity drugs. Under terms of a deal announced late Friday, Pfizer will acquire Metsera for up to $86.25 per share, or more than $10 billion. Pfizer will pay $6 ...